Recent News

• 10.29.2025 - Addex Increases Issued Share Capital to Create Treasury Shares
• 09.30.2025 - Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update
• 09.26.2025 - Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025
• 09.23.2025 - Addex Appoints Bank of New York Mellon as Depositary Bank
• 06.30.2025 - Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders
• 06.25.2025 - Addex Shareholders Approve All Resolutions at Annual General Meeting
• 06.19.2025 - Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update
• 06.18.2025 - Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025
• 06.06.2025 - Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models

Recent Filings

• 09.30.2025 - EX-99.1 EX-99.1
• 09.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 09.23.2025 - EX-99.1 EX-99.1
• 09.23.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.30.2025 - EX-99.1 EX-99.1
• 06.25.2025 - EX-99.1 EX-99.1
• 06.25.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.23.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 06.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]